Inappropriate use of inhaled short acting beta-agonists and its association with patient health status

Author： Hong Song Hee Sanders Brittany H. West Donna

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.22, Iss.1, 2006-01, pp. : 33-40

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Observational Study of the Additive Effects of Pranlukast on Inflammatory Markers of Clinically Stable Asthma with Inhaled Corticosteroids and Long-Acting Beta 2 Agonists

Respiration, Vol. 76, Iss. 4, 2008-08 ,pp. : 398-402

Karger

Access to resources Recommend Favorite

Evaluating Safety of Long-Acting Beta Agonists (LABAs) in Patients with Asthma

Current Drug Safety, Vol. 5, Iss. 3, 2010-07 ,pp. : 245-250

Bentham Science Publishers

Access to resources Recommend Favorite

Long‐acting muscarinic antagonist + long‐acting beta agonist versus long‐acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta‐analysis

RESPIROLOGY (ELECTRONIC), Vol. 20, Iss. 8, 2015-11 ,pp. : 1153-1159

John Wiley & Sons Inc

Access to resources Recommend Favorite

Differential Effects of Short-Acting β₂-Agonists on Human Granulocyte Functions

International Archives of Allergy and Immunology, Vol. 139, Iss. 1, 2005-11 ,pp. : 1-8

Karger

Access to resources Recommend Favorite

Indacaterol, a novel inhaled, once-daily, long-acting beta 2 -agonist for the treatment of obstructive airways diseases

By Beeh Kai

Advances in Therapy, Vol. 26, Iss. 7, 2009-07 ,pp. : 691-699

Springer Publishing Company

Access to resources Recommend Favorite